We conclude that induction of p53 might explain the positive therapeutic effect of Selinexor in the treatment of AML with NPMmut, possibly in combination with other p53-inducing agents, such as mdm2/p53 inhibitors, e.g., nutlin-3a [43]. This evidence concerns the gene TP53 and acute myeloid leukemia.